0.91
-0.0277(-2.95%)
Currency In USD
| Previous Close | 0.94 |
| Open | 0.95 |
| Day High | 0.97 |
| Day Low | 0.91 |
| 52-Week High | 1.45 |
| 52-Week Low | 0.7 |
| Volume | 96,734 |
| Average Volume | 250,290 |
| Market Cap | 33.45M |
| PE | -2.54 |
| EPS | -0.36 |
| Moving Average 50 Days | 0.96 |
| Moving Average 200 Days | 1.11 |
| Change | -0.03 |
If you invested $1000 in RenovoRx, Inc. (RNXT) since IPO date, it would be worth $125.73 as of February 21, 2026 at a share price of $0.913. Whereas If you bought $1000 worth of RenovoRx, Inc. (RNXT) shares 3 years ago, it would be worth $231.09 as of February 21, 2026 at a share price of $0.913.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RenovoRx Establishes RenovoCath® Medical Advisory Board
GlobeNewswire Inc.
Feb 10, 2026 1:30 PM GMT
Advisory Board Members Will Provide Strategic Clinical Insights to Further Advance the TAMP™ Therapy Platform in Clinical Indications of High Unmet Medical NeedMOUNTAIN VIEW, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or t
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
GlobeNewswire Inc.
Feb 05, 2026 1:30 PM GMT
Appointment Strengthens RenovoRx’s C-Suite Leadership to Support Commercial Growth of RenovoCath®MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developin
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
GlobeNewswire Inc.
Feb 04, 2026 1:30 PM GMT
Results Support TAMP’s Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-DeliveryMOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“